Good response to pentamidine isethionate in a case of Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis that was difficult to treat: Case Report.
Benivaldo Ramos Ferreira TerceiroTania Salgado de Souza TorracaFrederico Pereira Bom BragaAna Cristina da Costa MartinsLucia Regina BrahimMauricio Naoto SahekiLuciana de Freitas Campos MirandaArmando de Oliveira SchubachClaudia Maria Valete-RosalinoPublished in: Revista da Sociedade Brasileira de Medicina Tropical (2019)
In Brazil, meglumine antimoniate is the first drug of choice for mucosal leishmaniasis treatment followed by amphotericin B and pentamidine isethionate. We report the case of a patient with severe mucosal lesions caused by Leishmania (Viannia) braziliensis that were difficult to treat. Over a 14-year period, the patient showed low adherence and three treatment attempts with meglumine antimoniate failed. Additionally, there was an unsatisfactory response to liposomal amphotericin B and nephrotoxicity when using amphotericin B deoxycholate that persisted after new treatment attempt with liposomal amphotericin B. Finally, healing was achieved with pentamidine isethionate and maintained during nine months of monitoring.